Clinical trial

Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation…

NCT00075582 · Children's Oncology Group, Other · Completed

Key facts

NCT number NCT00075582
Title Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
Official title Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma
Lead sponsor Children's Oncology Group, Other
Collaborators National Cancer Institute (NCI) NIH
Status Completed
Phase Phase 3
Study type Interventional
Conditions Adult Rhabdomyosarcoma, Embryonal Childhood Rhabdomyosarcoma, Embryonal-botryoid Childhood Rhabdomyosarcoma, Previously Untreated Childhood Rhabdomyosarcoma
Intervention type Drug, Procedure, Radiation
Interventions conventional surgery, dactinomycin, cyclophosphamide, vincristine sulfate, radiation therapy
Enrollment 390
Start date Sep 4, 2004
Primary completion Aug 13, 2012
Completion Sep 30, 2021
First posted Jan 12, 2004
Last update posted Nov 19, 2021
Countries Australia, Canada, New Zealand, Puerto Rico, Switzerland, United States

At a glance

  • 100–999 Study sites
  • Yes Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies